CCL5 mediates target‐kinase independent resistance to FLT3 inhibitors in FLT3‐ITD‐positive AML

FLT3‐ITD tyrosine kinase inhibitors (TKI) show limited clinical activity in acute myeloid leukemia (AML) due to emerging resistance. TKI resistance is mediated by secondary FLT3‐ITD mutations only in a minority of cases. We hypothesize that the cytokine CCL5 protects AML cells from TKI‐mediated cell death and contributes to treatment resistance. We generated PKC412‐ and sorafenib‐resistant MOLM‐13 cell lines as an in vitro model to study TKI resistance in AML. Increased CCL5 levels were detected in supernatants from PKC412‐resistant cell lines compared to TKI‐sensitive cells. Moreover, CCL5 treatment of TKI‐sensitive cells induced resistance to PKC412. In resistant cell lines with high CCL5 release, we observed a significant downregulation of the CCL5‐receptor CCR5 and CXCR4. In these cell lines, TKI resistance could be partly overcome by addition of the CXCR4‐receptor antagonist plerixafor. Microarray and intracellular flow cytometry analyses revealed increased p‐Akt or p‐Stat5 levels in PKC412‐resistant cell lines releasing high amounts of CCL5. Treatment with the CXCR4 antagonist plerixafor, αCCL5, or CCR5‐targeting siRNA led to a decrease of p‐Akt‐positive cells. Transient transfection of sensitive MOLM‐13 cells with a CCL5‐encoding vector mediated resistance against PKC412 and led to an increase in p‐Akt‐positive and p‐Stat5‐positive cells. Isolated AML blasts from patients treated with PKC412 revealed that CCL5 transcript levels increase significantly at relapse. Taken together, our findings indicate that CCL5 mediates resistance to FLT3‐TKIs in FLT3‐ITD‐mutated AML and could possibly serve as a biomarker to predict drug resistance.

[1]  Ø. Bruserud,et al.  High Constitutive Cytokine Release by Primary Human Acute Myeloid Leukemia Cells Is Associated with a Specific Intercellular Communication Phenotype , 2019, Journal of clinical medicine.

[2]  A. Thakor,et al.  Mesenchymal stem cells confer chemoresistance in breast cancer via a CD9 dependent mechanism , 2019, Oncotarget.

[3]  Qun He,et al.  Infiltrating CD4+ T cells attenuate chemotherapy sensitivity in prostate cancer via CCL5 signaling , 2019, The Prostate.

[4]  Fang Yang,et al.  PAI‐1 induces Src inhibitor resistance via CCL5 in HER2‐positive breast cancer cells , 2018, Cancer science.

[5]  M. Pocard,et al.  CCL2/CCL5 secreted by the stroma induce IL-6/PYK2 dependent chemoresistance in ovarian cancer , 2018, Molecular Cancer.

[6]  M. Levis,et al.  Mechanisms of Resistance to FLT3 Inhibitors and the Role of the Bone Marrow Microenvironment. , 2017, Hematology/oncology clinics of North America.

[7]  C. Bloomfield,et al.  Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation , 2017, The New England journal of medicine.

[8]  G. Garcia-Manero,et al.  Metabolic alterations and drug sensitivity of tyrosine kinase inhibitor resistant leukemia cells with a FLT3/ITD mutation. , 2016, Cancer letters.

[9]  S. Dan,et al.  Serum VEGF-A and CCL5 levels as candidate biomarkers for efficacy and toxicity of regorafenib in patients with metastatic colorectal cancer , 2016, Oncotarget.

[10]  Li Meng,et al.  Cisplatin-induced CCL5 secretion from CAFs promotes cisplatin-resistance in ovarian cancer via regulation of the STAT3 and PI3K/Akt signaling pathways. , 2016, International journal of oncology.

[11]  K. Stegmaier,et al.  Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML , 2015, Oncogene.

[12]  Elizabeth C. Townsend,et al.  Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia , 2015, Science Advances.

[13]  M. Caligiuri,et al.  Receptor tyrosine kinase Axl is required for resistance of leukemic cells to FLT3-targeted therapy in acute myeloid leukemia , 2015, Leukemia.

[14]  M. Konopleva,et al.  Secondary mutations as mediators of resistance to targeted therapy in leukemia. , 2015, Blood.

[15]  Matthew E. Ritchie,et al.  limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.

[16]  A. Ben-Baruch,et al.  The chemokine system, and its CCR5 and CXCR4 receptors, as potential targets for personalized therapy in cancer. , 2014, Cancer letters.

[17]  David A. Williams,et al.  Cytokines secreted by bone marrow stromal cells protect c-KIT mutant AML cells from c-KIT inhibitor-induced apoptosis , 2014, Leukemia.

[18]  M. Levis,et al.  Bone marrow stroma‐mediated resistance to FLT3 inhibitors in FLT3‐ITD AML is mediated by persistent activation of extracellular regulated kinase , 2014, British journal of haematology.

[19]  T. Deguchi,et al.  CCR1/CCL5 interaction promotes invasion of taxane-resistant PC3 prostate cancer cells by increasing secretion of MMPs 2/9 and by activating ERK and Rac signaling. , 2013, Cytokine.

[20]  E. Sison,et al.  Dynamic Chemotherapy-Induced Upregulation of CXCR4 Expression: A Mechanism of Therapeutic Resistance in Pediatric AML , 2013, Molecular Cancer Research.

[21]  Stephen R. Piccolo,et al.  A single-sample microarray normalization method to facilitate personalized-medicine workflows. , 2012, Genomics.

[22]  W. Han,et al.  STAT3-RANTES Autocrine Signaling Is Essential for Tamoxifen Resistance in Human Breast Cancer Cells , 2012, Molecular Cancer Research.

[23]  A. Oriol,et al.  Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial. , 2012, Blood.

[24]  M. Lisanti,et al.  CCR5 antagonist blocks metastasis of basal breast cancer cells. , 2012, Cancer research.

[25]  A. Kasarskis,et al.  Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia , 2012, Nature.

[26]  T. Hadden,et al.  Akt, FoxO and regulation of apoptosis. , 2011, Biochimica et biophysica acta.

[27]  Chengsheng Zhang,et al.  Reversible Resistance Induced by FLT3 Inhibition: A Novel Resistance Mechanism in Mutant FLT3-Expressing Cells , 2011, PloS one.

[28]  E. Estey,et al.  Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  C. Peschel,et al.  Identification of a secondary FLT3/A848P mutation in a patient with FLT3-ITD-positive blast phase CMML and response to sunitinib and sorafenib , 2010, Leukemia.

[30]  A. Lokshin,et al.  Chemotherapeutic drugs and human tumor cells cytokine network , 2008, International journal of cancer.

[31]  Tullio Pozzan,et al.  CXCR4–CCR5: A couple modulating T cell functions , 2008, Proceedings of the National Academy of Sciences.

[32]  D. Gilliland,et al.  Uniform sensitivity of FLT3 activation loop mutants to the tyrosine kinase inhibitor midostaurin. , 2007, Blood.

[33]  Ø. Bruserud,et al.  Subclassification of patients with acute myelogenous leukemia based on chemokine responsiveness and constitutive chemokine release by their leukemic cells. , 2007, Haematologica.

[34]  H. Schaller,et al.  RANTES stimulates Ca2+ mobilization and inositol trisphosphate (IP3) formation in cells transfected with G protein‐coupled receptor 75 , 2006, British journal of pharmacology.

[35]  Anita Ryningen,et al.  T lymphocyte chemotactic chemokines in acute myelogenous leukemia (AML): local release by native human AML blasts and systemic levels of CXCL10 (IP-10), CCL5 (RANTES) and CCL17 (TARC) , 2006, Cancer Immunology, Immunotherapy.

[36]  Y. Kimura,et al.  The interplay between gastric cancer cell lines and PBMCs mediated by the CC chemokine RANTES plays an important role in tumor progression. , 2005, Journal of experimental & clinical cancer research : CR.

[37]  W. Bornmann,et al.  A cell-based screen for resistance of Bcr-Abl-positive leukemia identifies the mutation pattern for PD166326, an alternative Abl kinase inhibitor. , 2005, Blood.

[38]  M. Norcross,et al.  Constitutive association of cell surface CCR5 and CXCR4 in the presence of CD4 , 2004, Journal of cellular biochemistry.

[39]  G. Ehninger,et al.  Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. , 2002, Blood.

[40]  M. Weil,et al.  The CC chemokine RANTES in breast carcinoma progression: regulation of expression and potential mechanisms of promalignant activity. , 2002, Cancer research.

[41]  A. Hutchinson,et al.  Evaluation of the G protein coupled receptor-75 (GPR75) in age related macular degeneration , 2001, The British journal of ophthalmology.

[42]  L. Mitnaul,et al.  CCR5, CXCR4, and CD4 Are Clustered and Closely Apposed on Microvilli of Human Macrophages and T Cells , 2001, Journal of Virology.

[43]  Jean Salamero,et al.  HIV Coreceptor Downregulation as Antiviral Principle: SDF-1α–dependent Internalization of the Chemokine Receptor CXCR4 Contributes to Inhibition of HIV Replication , 1997, The Journal of experimental medicine.

[44]  D. Small,et al.  Mechanisms of resistance to FLT 3 inhibitors , 2016 .

[45]  M. Levis,et al.  Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors , 2013, Leukemia.

[46]  R. Stone,et al.  Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain. , 2006, Blood.